We believe that the development of DIVA represents an important step toward establishing a meaningful early diagnostic test for breast cancer, and that plasma DNMT1 activity shows promise as a biomarker for both tumor burden assessment and treatment monitoring in clinical perspective. This evidence concerns the gene DNMT1 and breast carcinoma.